Literature DB >> 32484006

Advanced High-Content-Screening Applications of Clonogenicity in Cancer.

Hector Esquer1, Qiong Zhou1, Adedoyin D Abraham1, Daniel V LaBarbera1.   

Abstract

Since its first report in 1956 by Puck and Marcus, the clonogenic assay has not been completely adapted into high-content-screening (HCS) workflows despite the numerous automated systems available. Initially, clonogenic assays were used to observe the effects of radiation on cell survival, particularly with cancer cells. The clonogenic assay has since been well characterized as a measure of cancer stem cell (CSC) stemness, demonstrating that a single CSC can generate clonogenic colonies. CSCs are highly tumorigenic with an unlimited proliferation potential and capacity to generate malignant tumors. Furthermore, CSCs are also known to resist conventional chemotherapy as well as more contemporary targeted therapies alike. Therefore, given the complexity of CSCs and their clinical relevance, new methods must follow to more effectively study and characterize CSC mechanisms that allow them to proliferate and persist, and to develop drugs and other therapies that can more effectively target these populations. Herein, we present a HCS method to quantify the number and size of colonies in 2D and 3D culture models and to distinguish colonies based on fluorescent markers using an Opera Phenix high-content-screening system. In addition, we present a method to scan at low magnification and rescan at a higher magnification to capture in greater detail colonies or even single cells of interest. These methods can be adapted to numerous applications or other imaging systems to study CSC biology using high-content analysis and for high-throughput drug discovery.

Entities:  

Keywords:  2D and 3D clonogenic assay; cancer stem cells (CSCs); drug discovery; high-content screening (HCS)

Mesh:

Year:  2020        PMID: 32484006     DOI: 10.1177/2472555220926921

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  2 in total

1.  Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L.

Authors:  Brett J Prigaro; Hector Esquer; Qiong Zhou; Laura A Pike; Paul Awolade; Xin-He Lai; Adedoyin D Abraham; Joshua M Abbott; Brock Matter; Uday B Kompella; Wells A Messersmith; Daniel L Gustafson; Daniel V LaBarbera
Journal:  J Med Chem       Date:  2022-02-22       Impact factor: 7.446

2.  In vitro chemosensitivity of a canine tumor venereal transmissible cancer cell line.

Authors:  Moisés Armides Franco Molina; Edson Antonio Santamaría-Martínez; Silvia Elena Santana Krimskaya; Diana Ginette Zarate-Triviño; Jorge R Kawas; Yareellys Ramos Zayas; Natanael Palacios Estrada; Heriberto Prado García; Paola Leonor García Coronado; Cristina Rodríguez Padilla
Journal:  Front Vet Sci       Date:  2022-08-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.